BBWI Stock Analysis: Bath & Body Works | NYSE
Specialty Retail | NYSE, USA | Market Cap: 3.317m USD | 12M Return: -34.7% | US0708301041 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 110M
EPS Trend: 16.8%
Qual. Beats: 1
Rev. Trend: -86.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bath & Body Works, Inc. (BBWI) is a U.S.-based specialty retailer focused on personal care and home fragrance products. Its merchandise spans 3-wick candles, home fragrance diffusers, fine fragrance mists, eau de parfum, body wash, hand soaps, body lotions and creams, and sanitizers, sold primarily under the Bath & Body Works brand through a combination of company-operated retail stores, e-commerce sites in the U.S. and Canada, and international partner-operated stores via franchise, license, and wholesale arrangements. The company was originally founded in 1963 and is headquartered in Columbus, Ohio, having previously operated as L Brands, Inc. before rebranding in August 2021.
BBWI is classified in the Consumer Discretionary sector within the Other Specialty Retail sub-industry, reflecting its position as a non-grocery, brand-driven retailer rather than a mass-market general merchandiser. The companys business model combines a vertically integrated direct-to-consumer retail footprint-which gives it control over pricing, merchandising, and customer data-with a capital-light international expansion strategy that relies on third-party operators to extend brand reach into markets where it does not own stores.
- Candle and home fragrance category anchors comparable sales growth
- Input cost inflation and tariffs pressure gross margins
- International franchise expansion diversifies revenue mix
| Net Income: 781.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 3.73 > 1.0 |
| NWC/Revenue: 4.76% < 20% (prev 5.47%; Δ -0.71% < -1%) |
| CFO/TA 0.25 > 3% & CFO 1.27b > Net Income 781.0m |
| Net Debt (5.08b) to EBITDA (1.45b): 3.50 < 3 |
| Current Ratio: 1.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (202.0m) vs 12m ago -4.54% < -2% |
| Gross Margin: 44.12% > 18% (prev 44.60%; Δ -0.48% > 0.5%) |
| Asset Turnover: 144.6% > 50% (prev 153.1%; Δ -8.46% > 0%) |
| Interest Coverage Ratio: 4.49 > 6 (EBIT TTM 1.21b / Interest Expense TTM 269.0m) |
| A: 0.07 (Total Current Assets 2.05b - Total Current Liabilities 1.71b) / Total Assets 5.16b |
| B: -0.24 (Retained Earnings -1.21b / Total Assets 5.16b) |
| C: 0.24 (EBIT TTM 1.21b / Avg Total Assets 4.99b) |
| D: -0.17 (Book Value of Equity -1.05b / Total Liabilities 6.21b) |
| Altman-Z'' = 1.12 = BB |
| DSRI: 1.20 (Receivables 154.0m/131.0m, Revenue 7.21b/7.37b) |
| GMI: 1.01 (GM 44.60% / 44.12%) |
| AQI: 0.92 (AQ_t 0.19 / AQ_t-1 0.21) |
| SGI: 0.98 (Revenue 7.21b / 7.37b) |
| TATA: -0.10 (NI 781.0m - CFO 1.27b) / TA 5.16b) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of October 03, 2026, the stock is trading at USD 16.06 with a total of 5,653,229 shares traded. Over the past week, the price has changed by -2.37%, over one month by -13.33%, over three months by -26.11% and over the past year by -34.70%.
Current recommended Stop Loss: 15.10 (which is 6% or 1.3 ATR below the current price).
Bath & Body Works has received a consensus analysts rating of 3.85. Therefore, it is recommended to buy BBWI.
- StrongBuy: 7
- Buy: 4
- Hold: 8
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 24.1 | 49.8% |
P/E Trailing = 4.3176
P/E Forward = 6.2696
P/S = 0.4601
P/B = 1403.3759
P/EG = 0.6982
Revenue TTM = 7.21b USD
EBIT TTM = 1.21b USD
EBITDA TTM = 1.45b USD
Long Term Debt = 3.37b USD (from longTermDebt, last quarter)
Short Term Debt = 447.0m USD (from shortTermDebt, last quarter)
Debt = 5.87b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.13b
Net Debt = 5.08b USD (calculated: Debt 5.87b - CCE 794.0m)
Enterprise Value = 8.40b USD (3.32b + Debt 5.87b - CCE 794.0m)
Interest Coverage Ratio = 4.49 (Ebit TTM 1.21b / Interest Expense TTM 269.0m)
EV/FCF = 8.14x (Enterprise Value 8.40b / FCF TTM 1.03b)
FCF Yield = 12.28% (FCF TTM 1.03b / Enterprise Value 8.40b)
FCF Margin = 14.30% (FCF TTM 1.03b / Revenue TTM 7.21b)
Net Margin = 10.83% (Net Income TTM 781.0m / Revenue TTM 7.21b)
Gross Margin = 44.12% ((Revenue TTM 7.21b - Cost of Revenue TTM 4.03b) / Revenue TTM)
Gross Margin QoQ = 45.71% (prev 42.60%)
Tobins Q-Ratio = 1.63 (Enterprise Value 8.40b / Total Assets 5.16b)
Interest Expense / Debt = 4.58% (Interest Expense 269.0m / Debt 5.87b)
Taxrate = 19.57% (190.0m / 971.0m)
NOPAT = 970.8m (EBIT 1.21b * (1 - 19.57%))
Current Ratio = 1.20 (Total Current Assets 2.05b / Total Current Liabilities 1.71b)
Debt / Equity = -5.57 (negative equity) (Debt 5.87b / totalStockholderEquity, last quarter -1.05b)
Debt / EBITDA = 3.50 (Net Debt 5.08b / EBITDA 1.45b)
Debt / FCF = 4.93 (Net Debt 5.08b / FCF TTM 1.03b)
Total Stockholder Equity = -1.26b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.67% (Net Income 781.0m / Total Assets 5.16b)
RoE = -61.76% (negative equity) (Net Income TTM 781.0m / Total Stockholder Equity -1.26b)
RoCE = 57.44% (EBIT 1.21b / Capital Employed (Equity -1.26b + L.T.Debt 3.37b))
RoIC = 27.46% (NOPAT 970.8m / Invested Capital 3.54b)
WACC = 6.23% (E(3.32b)/V(9.19b) * Re(10.74%) + D(5.87b)/V(9.19b) * Rd(4.58%) * (1-Tc(0.20)))
Discount Rate = 10.74% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.15 | Cagr: -4.87%
[DCF] Terminal Value 77.97% ; FCFF base≈931.8m ; Y1≈1.07b ; Y5≈1.57b
[DCF] Fair Price = 92.13 (EV 23.7b - Net Debt 5.08b = Equity 18.6b / Shares 201.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 16.78 | EPS CAGR: 0.65% | SUE: 3.67 | # QB: 1
Revenue Correlation: -86.40 | Revenue CAGR: -0.95% | SUE: 0.39 | # QB: 0
EPS current Quarter (2026-10-31): EPS=0.11 | Chg30d=-55.06% | Revisions=-83% | Analysts=18
EPS current Year (2027-01-31): EPS=2.71 | Chg30d=+2.49% | Revisions=+24% | GrowthEPS=-15.5% | GrowthRev=-2.6%
EPS next Year (2028-01-31): EPS=2.79 | Chg30d=-2.63% | Revisions=-24% | GrowthEPS=+2.7% | GrowthRev=+1.7%
[Analyst] Revisions Ratio: -33% (up=14, down=29)